UroGen Pharma Dirección
Dirección controles de criterios 2/4
El CEO de UroGen Pharma's es Liz Barrett , nombrado en Jan 2019, tiene una permanencia de 5.25 años. compensación anual total es $1.87M, compuesta por 40.9% salario y 59.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.96% de las acciones de la empresa, por valor de $4.70M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 5.9 años, respectivamente.
Información clave
Liz Barrett
Chief Executive Officer (CEO)
US$4.6m
Compensación total
| Porcentaje del salario del CEO | 17.1% |
| Permanencia del CEO | 5.3yrs |
| Participación del CEO | 1.0% |
| Permanencia media de la dirección | 4.2yrs |
| Promedio de permanencia en la Junta Directiva | 6yrs |
Actualizaciones recientes de la dirección
Recent updates
UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Apr 09
UroGen: All Eyes On UGN-102
Mar 18UroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Mar 17UroGen Pharma Ltd. (NASDAQ:URGN) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 18UroGen gets FDA nod for extending duration of Jelmyto admixture
Sep 28UroGen Pharma (NASDAQ:URGN) Is In A Good Position To Deliver On Growth Plans
Mar 09We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate
Nov 04Is UroGen Pharma (NASDAQ:URGN) In A Good Position To Invest In Growth?
Jun 14What Does The Future Hold For UroGen Pharma Ltd. (NASDAQ:URGN)? These Analysts Have Been Cutting Their Estimates
May 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$5m | US$794k | -US$102m |
| Sep 30 2023 | n/a | n/a | -US$105m |
| Jun 30 2023 | n/a | n/a | -US$109m |
| Mar 31 2023 | n/a | n/a | -US$112m |
| Dec 31 2022 | US$2m | US$764k | -US$110m |
| Sep 30 2022 | n/a | n/a | -US$109m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | -US$113m |
| Dec 31 2021 | US$4m | US$739k | -US$111m |
| Sep 30 2021 | n/a | n/a | -US$113m |
| Jun 30 2021 | n/a | n/a | -US$111m |
| Mar 31 2021 | n/a | n/a | -US$117m |
| Dec 31 2020 | US$2m | US$637k | -US$128m |
| Sep 30 2020 | n/a | n/a | -US$137m |
| Jun 30 2020 | n/a | n/a | -US$130m |
| Mar 31 2020 | n/a | n/a | -US$121m |
| Dec 31 2019 | US$26m | US$695k | -US$105m |
Compensación vs. Mercado: La compensación total de Liz($USD4.64M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.41M).
Compensación vs. Ingresos: La compensación de Liz ha aumentado mientras la empresa no es rentable.
CEO
Liz Barrett (61 yo)
5.3yrs
Permanencia
US$4,639,589
Compensación
Ms. Elizabeth A. Barrett, also known as Liz, has been President, Chief Executive Officer and Director of UroGen Pharma Ltd. since January 3, 2019. She has been a Director at Allogene Therapeutics, Inc. sin...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.3yrs | US$4.64m | 0.96% $ 4.7m | |
| Chief Financial Officer | 2.2yrs | US$738.02k | 0.10% $ 502.7k | |
| General Counsel | 3.8yrs | US$1.51m | 0.069% $ 333.9k | |
| Senior Director of Investor Relations | no data | sin datos | sin datos | |
| Executive Vice President of Talent | less than a year | sin datos | sin datos | |
| Executive Vice President of Research & Development and Technical Operations | 4.2yrs | sin datos | sin datos | |
| Chief Medical Officer | 6.4yrs | US$1.36m | 0.41% $ 2.0m | |
| Chief Commercial Officer | 4.2yrs | sin datos | sin datos | |
| Executive Vice President of Regulatory Affairs & Quality | 4.2yrs | sin datos | sin datos | |
| Chief Business Officer | 3.7yrs | sin datos | sin datos | |
| Senior Vice President of Medical Affairs & Clinical Development | less than a year | sin datos | sin datos | |
| Consultant | 5.8yrs | US$3.86m | sin datos |
4.2yrs
Permanencia media
55.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de URGN se considera experimentado (3.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.3yrs | US$4.64m | 0.96% $ 4.7m | |
| Independent Director | 7yrs | US$193.76k | 0.044% $ 213.9k | |
| Independent Director | 6.6yrs | US$204.06k | 0% $ 0 | |
| Independent Director | 8.4yrs | US$201.53k | 0% $ 0 | |
| Independent Chairman | 11.4yrs | US$342.18k | 1.2% $ 5.8m | |
| Independent Director | 1.5yrs | US$192.72k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Chairman of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | less than a year | US$313.29k | sin datos | |
| Independent Director | 1.8yrs | US$194.41k | 0% $ 0 |
6.0yrs
Permanencia media
66.5yo
Promedio de edad
Junta con experiencia: La junta directiva de URGN se considera experimentada (5.9 años de antigüedad promedio).